Author of

• 15382

  +

  P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15465

    +

    P3.04-083 - FGFR1, 2 and 3 Expression in Early Stage Non-Small-Cell Lung Cancer (ID 837)

    09:30 - 09:30  |  Author(s): R. Bernards
    • Abstract
    • Slides

    Background:
    The aim of this study was to identify the protein expression levels of Fibroblast Growth Factor Receptors (FGFR) 1, 2 and 3 in early-stage non-small-cell lung carcinoma (NSCLC). Additionally, we performed a screen to define the frequency of FGFR3-TACC3 translocation and FGFR3 amplification.
    
    Methods:
    Archived tissue from 653 NSCLC samples (adenocarcinoma (AC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC)) was analyzed with immunohistochemistry (IHC) for expression of FGFR1, 2 and 3. Expression levels of FGFR1, 2 and 3 were then correlated with clinicopathological features. The presence of FGFR3-TACC3 translocation was detected with RT-PCR and FGFR3 amplification was detected with FISH.
    
    Results:
    High protein expression of FGFR1, 2 and 3 was shown in 65 (10.5%), 78 (12.9%) and 20 (3.2%) of NSCLC tumor samples, respectively. Expression of FGFR1 was associated with light smoking (p = 0.007), AC (p < 0.000) and worse overall survival (p < 0.04). Expression of FGFR2 was associated with female sex (p < 0.001), younger age (p = 0.01) and AC (p < 0.000). Expression of FGFR3 was associated with male sex (p = 0.047), older patients (p = 0.01) and SCC (p < 0.000). FGFR3-TACC3 fusion was shown in 2.8% (6/210). In 45 FGFR3 IHC positive samples, two samples were FGFR3 amplified (4.4%) and one showed gain (2.2%).
    
    Conclusion:
    We show that FGFR1, 2 and 3 proteins are expressed in a significant number of NSCLC and identify some of the underlying molecular mechanisms. FGFR1 (but not FGFR2 and 3) protein overexpression is correlated with significant worse overall survival. FGFR1, 2 and 3 protein overexpression may become a new target of treatment in patients with NSCLC.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.